This regimen should be studied in patients with advanced ACC, especially tumors with higher expression of Ki67, MELK, CDK1, CDK2, their partnering cyclins, FOXM1, STMN1, and CTNNB1. Here, MKI67 is linked to adrenal cortex carcinoma.